Study: Taking Vitamins Can Save Your Life and Destroy Disease

Like:

In December 1993, four reports appeared describing the ecology of macular degeneration (MD). (1-4) It was generally agreed that the environmental contribution includes sunlight. It was suggested that the antioxidants serve to counter the oxidative damage. In any case, the articles prompted a letter to the editor entitled, “Now That We Have All The Pieces… Why Is There Still A Puzzle?” (5) This was intended to indicate that we still have very little opportunity to slow and/or stop the degenerative process. We have even less knowledge about how to reverse and/or prevent MD.

This report is intended to cast additional light on the subject It is suggested that, viewed in the bigger picture, the total body concept, significant changes in macular degeneration and other diseases may occur when larger-than-recommended amounts of the antioxidants are supplied. Additionally, it is proposed that the therapy be instituted for longer periods of time and begun earlier in life. It is hoped that this report will continue more action in the pursuit of this approach to macular degeneration.

Introduction
The literature is replete with information which suggests that a common denominator in the aging process and in the major diseases associated with aging is oxidative damage. This has led to an interest in the use of antioxidants in the prevention and treatment of such problems. There are hundreds, if not thousands, of articles on this subject. Some are retrospective; other prospective. They deal with large and small samples of short and long duration. They range from the womb to the tomb. Most of them are of an epidemiologic (correlational) nature. However, many are concerned with intervention and possibly provide causal data.

This report will outline evidence to show that the antioxidants are necessary, singly, in combinations, in larger amounts than generally held, and must be started much earlier in life. Hence, we will attempt to emphasize the relationship of antioxidants to common disorders such as heart disease, cancer, diabetes, arthritis, cataracts, and macular degeneration as well as other syndromes through an examination of 40 representative studies in the English language literature.

Vitamin A Studies
Included (Table 1) are five representative studies of vitamin A consumption in health and disease. (6-10) According to the Subcommittee on Foods and Nutrition of the National Research Council, the daily recommended requirements (RDA) for vitamin A are 5,000 and 4,000 IU respectively for men and women. (11) It is clear from Table 1 that much larger amounts than proposed for healthy people in the RDA are needed. Additionally, the evidence from these studies suggest that there were no side effects.

It is generally recognized that vitamin A blood levels below 10 mcg% are considered evidence of obvious deficiency. (12)  Olson contends that the normal range is 20 to 50 mcg% and therefore anything above 50 is high.

Table 2 summarizes the studies on vitamin A in the blood in health and sickness.  You will note that the reports shown suggest that what Olson call high levels are probably the desired amounts.

Vitamin C Studies
According to the Recommended Dietary Allowances, 60 mg of vitamin C is the suggested normal requirement. (11)Table 3 features studies which underscore the desirability of larger-than-recommended amounts. (18-22)  It will be noted that amounts as large as three grams per dose provide remarkable consequences.

Back in the ’40s, the Interdepartmental Committee on Nutrition for National Defense (ICNND) began to set the standards for optimal plasma vitamin C. Originally, acceptability was anything above 0.1 mg%. Through the ’40s, the figures were changed to 0.2 and then 0.4 mg%. Most of the literature today considers 0.4 mg% as being a satisfactory blood vitamin C level. In this connection, Block points out that 15% of white men, 65-74 years of age, in the U.S. today have blood ascorbate levels below 0.4 mg%.(23)  Chandra views 0.5 to 2.0 mg% as the acceptable range. (24) It is clear from Table 4 that the best clinical results parallel plasma levels above 1.0 mg%. (17, 25-28)

Vitamin E Studies
According to the RDA, 30 mg of vitamin E or 10 mg of alpha tocopherol is considered the recommendation for healthy man.(11) It will be noted (Table 5) that amounts ranging from 400 to 3200 mgs contribute to the solution of many classical problems. (29-33)

There is not much in the literature regarding the optimal blood vitamin E levels. MachIm, in his book (34) indicates that anything less than 0.7 mg% is deficient, levels between 0.7 and 0.9 are low, and values above 0.9 mg% are acceptable. Simonoff adds the fact that the blood levels of vitamin E are different in the sexes and at different ages. (35)  For example, in the young adult, the values should be 1.6 to 1.9 mg% and decrease with age to 0.9 to 1.1 mg% in the elderly. In the light of these so-called norms, it is interesting (Table 6) that salutary effects seem to parallel higher blood vitamin E levels. (14, 36-39)

Other Antioxidants
While vitamins A, C, and E have been recognized for a long time for their antioxidant properties, there are others such as zinc, selenium, and bioflavinoids which directly or indirectly serve as free radical scavengers. Perhaps the one receiving the most attention at the moment is the carotenoids and particularly beta carotene. Since beta carotene serves as a provitamin A, there are suggestions as to its daily requirement. (11) However, beta carotene also serves an independent function as an antioxidant. The requirement in this regard is not very clear.

Table 7 outlines the relationship of dietary beta carotene to some of our major problems. (40-44) There seems to be no question but that beta carotene in larger-than-generally recommended amounts exert salutary effects.

In line with our earlier format, Table 8 outlines the blood carotene levels. (14, 45-48) In general, the levels in health are considerably larger than those with illness.

The Antioxidant Index
Perhaps more importantly is the observation that the relationship between various antioxidants in health and disease are sharpened when they are viewed as an antioxidant index. For example, macular degeneration, (26) colorectal adenomas, (49) rheumatoid arthritis, (50) cancer, (51) and cardiovascular disease, (52) become even more meaningful when viewed in terms of conditions of antioxidants rather than single ones.

Comments
We have been trying to answer the question of the role of antioxidants in the aging process and in age-related diseases. We think that we have some of the answers. It would seem, from what has transpired, that the antioxidants are important in the prevention and treatment of these problems. However, there are still unanswered questions. We still do not know all of the antioxidants. We are still not sure of the dosages except that they are larger than usually recommended. We have little information about the amounts for different diseases. For example, are the dosages larger for macular degeneration than heart disease? Or, are the amounts more a function of the oxidative damage? And, perhaps more importantly, we do not have the time frame period.

Since the disturbances associated with aging and these age-related diseases are characterized by a long incubation period and an insidious clinical course, the question of when one should institute an antioxidant program is still unresolved. The one thing we know for sure is starting when the disease appears is too late.

Summary and Conclusions
In the final analysis, how we fare is a function of two sets of interdependent factors. On the one hand, we are at the mercy of numerous environmental threats, such as physical, chemical, microbial, thermic, actinic, and psychologic. For macular degeneration, the dominant one is solar radiation; for lung cancer, it is tobacco consumption. However, how we fare is also a function of how well we tolerate these environmental challenges. These protective systems are collectively referred to as resistance/susceptibility, constitution, predisposition, immunocompetence, homeostasis and/or harmony. The antioxidants serve as an important ingredient in building resistance and reducing susceptibility and largely because of its free radical scavenging action. However, how much, when and for how long are still the burning questions. At the moment, in the light of these 40 representative studies, macular degeneration and cataracts enjoy positions like heart disease and cancer.

(Table 1 in the original paper contains Dietary Vitamin A Levels)

Reference # 6/ Precancer
In a study of oral leukoplakia, patients were given 200,000 IU of vitamin A per week for six months versus placebo capsules. Fifty-seven per cent of vitamin A supplemented patients had complete remission and, during that time, no new lesions appeared.

#7/HIV
A study was done with 25 HIV patients with CD4+ T cell counts less than 800. Thirty-two per cent of the subjects had retinol levels less than 30 mcg%. Subjects taking a daily multivitamin containing modest amounts of vitamin A (1500-2100 mcg) had higher serum retinol levels than those taking no supplements (72 versus 42 mcg%). These observations suggest that even modest doses of vitamin A can have significant impact on serum retinol levels in advanced HIV patients.

#8/ Cancer
A case control study conducted among a cohort of chemical manufacturing employees provided an opportunity to test the hypothesis that lung cancer risk is inversely related to dietary intake of vitamin A. Subjects in the lowest tercile of vitamin A intake (less than 62,000 lU/week) had approximately twice the risk of lung cancer as those in the highest (greater than 100,000 IUI week).

#9/Respiratory Tract Infections
Preschool-age children (157) with a history of frequent respiratory illness were randomized into vitamin A supplemented (450 mcg/day) and placebo groups. Respiratory symptoms were recorded on a daily basis over a period of 11 months. The children who received the supplement experienced 19% fewer episodes of respiratory symptomatology than their placebo counterparts.

#10/Mortality
Mortality of Sumatran children randomized to receive a 200,000 IU vitamin A capsule (n=9776) was compared with those who did not (n=2447). During the four months after completion of the first distribution, mortality among the recipients was 75 per cent less than the nonrecipients. One capsule every six months may provide adequate protection for the vast majority of children.

(Table 2 in the original paper contains Blood Vitamin A Levels)

Reference # 13/Measles
In a study of children in Long Beach, California, the blood levels in youngsters with measles was 24 mcg%; in those with nonmeasles 26 mcg%; and in the well kids 40 mcg%.

#14/ Alzheimer’s Disease
Elderly people with Alzheimer’s Disease post-infarct-dementia and controls were examined. The average vitamin A levels were 45 mcg% in Alzheimer’s Disease compared to an average 61 mcg% in the control group.

#15/ Cancer
The vitamin A blood levels of patients with pulmonary cancer, non-cancer pulmonary disease, and controls were compared. The levels were 45.6 mcg% (range 20.2 to 79.5) for the pulmonary cancer subjects; 64.3 mcg% (range 43.6 to 80.8) for the patients with noncancer pulmonary disease; and 68.4 mcg% (range 52.6 to 101.2) in the controls.

#16/ Bronchopulmonary Disease
This study showed that low vitamin A levels (less than 10 mcg%) observed in infants with bronchopulmonary dysplasia (BPD), and implies that therapeutic administration of vitamin A may help prevent and treat BPD.

#17/ Cardiovascular Disease
There is data from the cross-cultural European comparisons of the Edinburgh Aging Control Study and of the Basel Prospective Study. They show, for the first time with fair probability, that vitamin A concentrations needed to decrease ischemic heart disease risk are 63 to 80 mcg%.

(Table 3 in the original paper contains Dietary Vitamin C Levels)

Reference #18/Infertility
One gram of ascorbic acid per day for 60 days was provided to 20 clearly-diagnosed infertile, but otherwise healthy, men. A separate control group of 20 men were placebo-supplemented. At the end of these two months, conception occurred unanimously only in the vitamin C supplemented couples!

#19/Diabetes
A study of the small blood vessels of the skin and retina was carried out in 24 normal subjects and 12 diabetics. The experiment revealed very clearly that the capillary strength of both the eye and skin of all diabetics improved during the vitamin C treatment (one gram/day) and worsened when it was discontinued.

#20/Mental Illness
The manic/depressive state was assessed in 24 subjects who completed two generally accepted psychometric tests. Each patient was provided with either a three gram ascorbic acid effervescent tablet or a placebo. In the vitamin C treated group, the severity of the bipolar state was reduced within the first hour and then declined even more rapidly between the second and fourth hours. No change occurred in the placebo subset.

#21/Life Expectancy
In a reexamination of a large federal government study, it was discovered that those men who consumed 300 to 400 mgs of vitamin C daily compared with those who consumed less than 50 mgs showed art overall mortality reduction of 42% principally due to a decline in heart disease and cancer. This translates into living approximately six years longer!

#22/ Cardiovascular Disease
A 1000 mg ascorbic acid tablet or a placebo was supplemented daily to 20 adults for two six-week periods in a randomized, crossover design. Under these conditions, vitamin C supplementation reduced the systolic pressure.

(Table 4 in the original paper contains Blood Vitamin C Levels)

Reference #25/Periodontal Disease
In a study of 24 adult volunteers with initially low and partially even deficient plasma vitamin C values, the hydroxyproline and proline content was measured before and after supplementation. There was a statistically significant rise but not before the plasma ascorbate level was above 0.9 mg%. The optimal plasma vitamin C level which was associated with the highest hydroxyproline and proline content in periodontal tissue ranged between 1.0 and 1.3 mg%.

#17/Heart Disease
The most recent work on risk factors in ischemic heart disease (IHD) is available from several cross-cultural epidemiologic studies. They all suggest, for the first time with fair probability, that protection against IHD is paralleled by vitamin C levels in the range of 0.7 to 0.9 mg%.

#26/ Macular Degeneration
From the Eye Disease Case Control Study Group, there is evidence that blood levels of vitamin C in the 0.7 to 1.6 mg% range have a risk of one third to one half that in blood levels below 0.7 mg% for macular degeneration.

#27/ Hypertension
In a study of 685 patients without known hypertension, it was discovered that the higher the plasma vitamin C level, the lower the systolic and diastolic pressure. Specifically, with plasma ascorbic acid (PAA) of 0.7 mg%, the blood pressure was 147/83 mm Hg; with PAA of 1.4 mg%, the pressure was 139/78 mm Hg.

#28/ Cataracts
A classification was designed of three blood ascorbate levels; less than 0.7 mg%, greater than 1.6 mg%, and a group with plasma levels at intermediate range. Persons with the lowest ascorbate intake status had 11-fold the risk of developing cataracts in the posterior region of the lens as individuals with the highest ascorbate levels.

(Table 5 in the original paper contains Dietary Vitamin E Levels)

Reference #29/ Cardiovascular Disease
One of the major signs of peripheral arterial disease (PAD) is intermittent claudication. In a double-blind study, 1600 mgs of alpha tocopherol a day significantly reduced (66%) this important sign of cardiovascular disease.

#30/Parkinson’s Disease
A comparison was made of the clinical picture of Parkinson’s Disease as measured by a Unified Parkinson’s Disease Scale, in patients taking vitamin E in dosages from 400 to 3200 IU per day versus those not taking vitamin E. The overall and individual performance, mentation, activities of daily living, motor examination, and complications of daily living improved only in the supplemented group.

#31/Rheumatoid Arthritis
The use of 1200 mg per day of vitamin E was studied in rheumatoid arthritis patients in Austria. The evidence suggests a strong relationship between the consumption of vitamin E and a reduction in pain and stiffness.

#32/ Cataracts
A case control group of 175 cataract patients, 55 years of age or older, were matched with a like number of cataract-free subjects. The incidence of cataracts was shown to be half in those consuming more than 400 IU of vitamin E per day.

#33/Immune Response
The effect of daily vitamin E supplementation (800 IU alpha tocopherol for 30 days) on immune responses of 32 healthy subjects (60+ years old) was examined in a placebo-controlled, double-blind trial in a metabolic research unit. The data suggest that vitamin E supplementation improves immune responsiveness in healthy elderly.

(Table 6 in the original paper contains Blood Vitamin E Levels)

Reference #36/ Immune Response
In a metabolic unit, using a double blind protocol, immune response was studied in a group receiving vitamin E (8OOmg per day) versus placebo. The increased immunocompetence was matched by blood vitamin E levels which jumped from 1.1 to 3.1 mg%. No such change in blood vitamin E occurred in the control group (1.1 to 1.0 mg%).

#14/Alzheimer’s Disease
A comparison of vitamin E blood levels in Alzheimer’s Disease (0.8 mg%), infarct-dementia (0.7 mg%) and in a group of controls (1.3 mg%) indicates that the vitamin F levels in the healthy subjects are approximately double that in the sick people.

#37/ Cataracts
In the Baltimore Longitudinal Study on Aging; using a case control design, the prediction of cataracts correlated with serum vitamin E. Specifically, those with the lowest blood levels (0.8 mg%) had an odds ratio of almost double those in the upper terciles (1.3 mg%).

#38/ Macular Degeneration
In the Baltimore Longitudinal Study, it was shown that those with macular degeneration (MD) have alpha tocopherol levels of 0.8 versus 1.3 mg% in the quartile free of MD. Hence, macular degeneration occurs twice as often in patients with low levels.

#39/Diabetes
Blood levels following supplementation of 2000 IU of vitamin F daily for two weeks was studied. The average serum tocopherol increased from 1.48 to 5.06 mg/g. This is the first time levels over 5 mg/g in the blood have been reported.

(Table 7 in the original paper contains Dietary Beta Carotene Levels)

Reference #40/ Cardiovascular Disease
In the Nurses’ Health Study in which a cohort of 121,000 US female nurses ages 30-55 were followed, those who consumed more than 15-20 mg/day of beta carotene had 40% lower risk of stroke and 22% lower risk of heart attack, compared to women who reported eating less than 6 mg/day.

#41/ Cancer
At the moment, this is the largest study of dietary factors and lung cancer in nonsmokers. The evidence suggests that dietary beta carotene and raw fruits and vegetables reduce the risk of lung cancer in nonsmoking men and women.

#42/ Immune Response
Immune system response to short-term, high-dose beta carotene supplementation was examined. Supplements of 180 mg of beta carotene per day for two weeks increased the number of T4 lymphocytes (helper cells) and did not effect the T8 lymphocytes (suppressor cells).

#43/ Precancer
In a study of 24 people with oral leukoplakia, given 30 mg/day of beta carotene for 3 to 6 months, there was a 71% response rate. Of particular importance was the fact that no clinically significant toxicity was observed during this trial that could be attributable to beta carotene.

#44/Mortality
A study was conducted regarding the association between consumption of vegetables high in beta carotene and cardiovascular mortality in a prospective cohort of 1299 elderly Massachusetts residents. Those consuming the greatest amount (in the upper quartile) of beta carotene rich foods had one half the risk of cardiovascular mortality as those in the lowest quartile.

(Table 8 in the original paper contains Blood Carotenoid Levels)

Reference #14/ Alzheimer’s Disease
The blood carotene levels were 7 to 23 mcg% in Alzheimer’s Disease; 7 to 16 mcg% in multi-infarct dementia patients versus 7 to 82 mcg% in controls.

#45/ Precancer
In oral and pharyngeal cancer, the blood carotene levels were 39.5 in cases versus 61.5 mcg% in control patients.

#46/Measles
Beta carotene levels were 35.0 mcg% in children with measles and kerotomalacia versus 39.0 mcg% in kids with measles without kerotomalacia as compared with 64.0 mcg % in health controls.

#47/ Macular Degeneration
The Eye Disease Case Control Study Group discovered that the chances of having macular degeneration is reduced about half in those demonstrating the larger amounts of carotenoids in the blood (greater than 69 mcg%).

#48/ Cardiovascular Disease
A 12-year follow-up of cardiovascular mortality in the Basel Prospective Study revealed a significantly increased relative risk of ischemic heart disease and stroke of a magnitude of two-fold at initially low plasma levels of carotene (less than 12 mcg%) independent of the classical cardiovascular risk factors.

References

1. Alexander, L.J. Age-Related Macular Degeneration: The Current Understanding of the Status of Clinicopathology, Diagnosis and Management. Journal of the American Optometric Association 64:# 12, 822-837,-December 1993.

2. Richer, S.P. Is There a Prevention and Treatment Strategy for Macular Degeneration? Journal of the American Optometric Association 62:#12, 838-850, December 1993.

3. Kaminski, M.S., Yolton, D.P., Jordan, W.T., Yolton, R.L. Evaluation of Dietary Antioxidant Levels and Supplementation with ICAPS-Plus and Ocuvite. Journal of the American Optometric Association 64:12,862-870, December 1993.

4. Van der Hagen, A.M., Yolton, D.P., Kaminski, M.S., Yolton, R.L. Free Radicals and Antioxidant Supplementation: A Review of Their Roles in Age-Related Macular Degeneration. Journal of the American Optometric Association 64:#1 2, 871-878, December 1993

5. Cheraskin, E. Macular Degeneration: Now That We Have All The Pieces.. .Why is There Still a Puzzle? Journal of the American Optometric Association (to be published)

6. Stitch, H.F., Hornsby, A.P., Mathew, B., Sankaranarayana, R., Krishnannair, M. Response to Oral Leukoplakias to the Administration of Vitamin A. Cancer Letters 40:#1, 93-101, May 1988.

7. Ward, B.J., Humphrey, J.H., Clement, L., Chaisson, R.E. Vitamin A Status in HIV Infection. Nutrition Research 13: 157-166, 1993.

8. Bond, G.G., Thompson, F.E, Cook, R.R. Dietary Vitamin A and Lung Cancer: Results of a Case-Control Study Among Chemical Workers. Nutrition and Cancer 9:2 & 3, 109-121, 1987.

9. Pinnock, C.B., Douglas, R.M., Badcock, N.R. Vitamin A Status in Children Who are Prone to Respiratory Tract Infections. Australian Pediatric Journal 22:#2, 95-99, May 1986.

10. Tarwotjo, I., Sommer, A., West, K.P., Jr., Djunaedi, E., Mele, L., Hawkins, B., Aceh Study Group. Influence of Participation on Mortality in a Randomized Trial of Vitamin A Prophylaxis. American Journal of clinical Nutrition 45:#6, 1466-1471, June 1987.

11. Food and Nutrition Board/Commission of Life Sciences/National Research Council. Recommended Dietary Allowances. Tenth Edition. 1989. Washington D.C., National Academy Press

12. Olson, J.A. Vitamin A. IN: MachIm, L.J. Handbook of Vitamins: Nutritional, Biochemical and Clinical Aspects. 1984. New York, Marcel Dekker, Inc.

13. Arrieta, A.C., Zaleska, M., Stutman, H.R., Marks, M.I. Vitamin A Levels in Children with Measles in Long Beach, California. Journal of Pediatrics 12:#l, 75-78, July 1992.

14. Zaman, Z., Roche, S., Fieldman, P., Frost, P.G., Niriella, D.C., Cayley, A.C.D. Plasma Concentrations of Vitamins A and E and Cartotenoids in Alzheimer’s Disease. Age and Aging 21:2, 91-94, March 1992

15. Basu, T.K., Donaldson, D., Jenner, M., Williams, D.C., Sakula, A. Plasma Vitamin A in Patients with Bronchial Carcinoma. British Journal of Cancer 33:#l, 119-121 January 1976.

16. Editors. Low Plasma Vitamin A Levels in Preterm Neonates with Bronchopulmonary Dysplasia. Nutrition Reviews 44:#6, 202-204, June 1986.

17. Gey, K.F., Moser, U.K., Jordan, P., Stahelin, H.B., Eichholzer, M., Ludin, E. Increased Risk of Cardiovascular Disease at Suboptimal Plasma Concentrations of Essential Antioxidants: An Epidemiological Update with Special Attention on Carotene and Vitamin C. American Journal of Clinical Nutrition 57: 787S-808S, 1993.

18. Harris, W.A., Harden, T.E., Dawson, E.B. Apparent Effect of Ascorbic Acid Medication on Semen Metal Levels. Fertility and Sterility 32:#4, 455-459, 1979.

19. Cox, B.D., Butterfield, W.J.H. Vitamin C Supplements and Diabetic Cutaneous Capillary Fragility. British Medical Journal 3:#5977, 205-207, July 25, 1975.

20. Naylor, G.J., Smith, A.H.W. Vanadium: A Possible Aetiological Factor in Manic

Depressive Illness. Psychological Medicine 11:249-256, 1981.

21. Enstrom, JE., Kanim, L.D., Klein, M.A. Vitamin C Intake Among a Sample of the United States Population. Epidemiology 3 :3, 194-202, 1992.

22. Osilesi, 0., Trout, D.L., Ogunwole, J.O., Glover, E.E. Blood Pressure and Plasma Lipids During Ascorbic Acid Supplementation in Borderline Hypertensive and Normotensive Adults. Nutrition Research 11: 405-412,1991.

23.Block, G. Vitamin C, Cancer and Aging. Age 16:#2, 55-58, April 1993.

24. Chandra, R.K. Effect of Vitamin and Trace Element Supplementation on Immune Responses and Infection in Elderly Subjects. The Lancet340: 8828, 1124-1 127, November 7, 1992.

25. Buzina, R., Aurer-Kozelu, J., Srkak-Jorgic, D., Buhler, E., Gey, K.F. Increase of Gingival Hydroxyproline and Pro line by Improvement of Ascorbic Acid Status in Man. International Journal for Vitamin and Nutrition Research 56:#4, 367-372, 1986.

26. Eye Disease Case-Control Study Group. Antioxidant Status and Neovascular Age-Related Macular Degeneration. Archives of Opthamology 11 1:#l, 104-109, January1993. 

27. Jacques, P.F., Relationship of Vitamin C Status to Cholesterol and Blood Pressure. Annals of the New York Academy of Sciences 669: 205-214, 1992.

28.Jacques, P.F., Chylack, L.T., Jr. Epidemiologic Evidence of a Role for the Antioxidant Vitamins and Carotenoids in Cataract Prevention. American Journal of Clinical Nutrition 53: 3520S-3525S, 1991. 

29. Williams. H.T.G., Fenna, D., MacBeth, R.A. Alpha Tocopherol in the Treatment of Intermittent Claudication. Surgery, Gynecology and Obstetrics 132:#4, 662-666, April 1971.

30. Factor, S.A., Weiner, W.J. Retrospective Evaluation of Vitamin E Therapy in Parkinson’s Disease. Annals of the New York Academy of Sciences 570: 441-442, 1989.

31. Scherak, 0., Kolarz, G. Vitamin E and Rheumatoid Arthritis. Arthritis and Rheumatism 34:#9,1205-1206, September 1991.

32. Robertson, J.M., Donner, A.P., Trevithick, J.R. Vitamin E Intake and Risk of Cataracts in Humans. Annals of the New York Academy of Sciences 570: 372-382, 1989.

33. Meydani, S.N., Barklund, M.P., Liu, S., Meydani, M., Miller, R.A., Cannon, J.G., Morrow, F.D., Rocklin, R., Blumberg, J.B. Effect of Vitamin E Supplementation on Immune Responsiveness of Healthy Elderly Subjects. FASEB Journal 3: A1057, 1989. 

34. Machlin, L.J. Handbook of Vitamins: National, Biochemical and Clinical Aspects. 1984. New York, Marcel Dekker, Inc.

35. Simonff, M., Sergeang, C., Gamier, N., Moretto, P., Vlabador, Y., Simonoff, G., Conri, C. Antioxidant Status (Selenium), Vitamins A and E and Aging. EXS 62: 368-397, 1992.

36. Meydani, S.N., Barkiund, M.P., Liu, S., Meydani, M., Miller, R.A., Cannon, J.G., Morrow, F.D., Rocklin, R., Blumberg, J.B. Vitamin E Supplementation Enhances Cell-Mediated Immunity in Healthy Elderly Subjects. American Journal of Clinical Nutrition 52:#3, 557-563, September 1990. 

37. Vitale, S., West, S., Hallfrisch, J., Alston, C., Wang, F., Moorman, C., Muller, D., Singh, V., Taylor, H.R. Plasma Antioxidants and Risk of Cortical and Nuclear Cataract. Epidemiology 4:#3, 195-203, May 1993. 

38. West, S., Vitale, S., Hallfrisch, J., Munoz, B., Muller, D., Bressler, S., Bressler, N.M. Are Antioxidants or Supplements Protective for Age-Related Macular Degeneration? Archives of Opthamology 1 12:#2, 222-227, February 1994.

39. Bierenbaum, M.L., Noonan, F.J., Machlin, L.J., Machim, S., Stier, A., Watson, P.B., Naso, A.M., Fleischman, A.I. The Effect of Supplemental Vitamin Eon Serum Parameters in Diabetics, Post Coronary and Normal Subjects. Nutrition Reports International 31:#6, 1171-1180, June 1985.

40. Manson, J.E., Stampfer, M.J., Willett, W.C., et al. A Prospective Study of Antioxidant Vitamins and Incidence of Coronary Heart Disease in Women. Circulation 84:#4, 11-546, 1991. Abstract

41 Mayne, S.T., Janerish, D.T., Greenwald, P., Shorost, S., Tucci, C., Zaman, M.B., Melamed, M.R., Kiely, M., McKneally, M.F. Dietary Beta Carotene and Lung Cancer Risk in U.S. Nonsmokers. Journal of the National Cancer Institute 86:#1, 33-38, January 1984. 

42. Alexander, M., Newmark, H., Miller, R.G. Oral Beta Carotene Can Increase the Number of OKT4+ Cells in Human Blood. Immunology Letters 9:221-224, 1985. 

43. Garewal, H.S., Meyskens, F.L., Killen, D., Reeves, D., Kiersch, T.A., Ellerson, H., Strosberg, A., King, D., Steinbronn, K. Response of Oral Leukoplakia to Beta Carotene. Journal of Clinical Oncology 8:1715-1720, 1990.

44. Gaziano, M., Manson, J.E., Branch, L.G., LaMotte, F., Colditz, G.A., Buring, J.E., Hennekens, C.H. Dietary Beta Carotene and Decreased Cardiovascular Mortality in an Elderly Cohort. Journal of the American College of Cardiology 1 9:#3, (supplement A) 377A, March 1, 1992.

45. Ibrahim, K., Jafarey, N.A., Zuberi, S.J. Plasma Vitamin A and Carotene Levels in Squamous Cell Carcinoma of Oral Cavity and Oropharnyx. Clinical Oncology 3:203-207, 1977.

46. Laditan, A.A.O., Fafunso, M. Serum Levels of Vitamin A, Beta Carotene and Albumin in Children with Measles. East African Medical Journal 58:#l, 51-55, January 1981.

47. Eye Disease Case Control Study Group. Risk Factors for Neovascular Age-Related Macular Degeneration. Archives of Opthamology; I 10:#12, 1701-1708, December 1992. 

48. Gey, K.F., Stahelin, H.B., Eichholzer, M. Poor Plasma Status of Carotene and Vitamin C is Associated with Higher Mortality from Ischemic Heart Disease and Stroke: Basel Prospective Study. Clinical Investigator 71:#1, 3-6, January 1993.

49. Roncucci, L., DiDonato, P., Carati, L., Ferreri, A., Perini, M., Bertoni, G., Bedogni, G., Paris, B., Syanoni, F., Girola, M., Ponz de Leon, M. Antioxidant Vitamins or Lactulose for the Prevention of the Recurrence of Colorectal Adenomas. Diseases of the Colon and Rectum 36:#3, 227-234, March 1993.

50. Heliovaara, M., Knekt, P., Aho, K., Aaran, R.K., Aromaa, A. Serum Antioxidants and Risk of Rheumatoid Arthritis. Annals of the Rheumatic Diseases 53:#1, 51-53, January 1994.

51. Eichholzer, M., Stahelin, H.B., Gey, K.F. Inverse Correlation Between Essential Antioxidants in Plasma and Subsequent Risk to Develop Cancer, Ischemic Heart Disease and Stroke Respectively: 12-Year Follow-up of the Prospective Basel Study. EXS 62:398-410, 1992.

52. Manson, J.E., Stampfer, M.J, Willett, W.C., Colditz, G.A., Speizer, F.E., Hennekens, C.H. Antioxidant Vitamins and Secondary Prevention of Cardiovascular Disease in High Risk Women. Circulation 88:#4, (Part 2), 1-70, October 1993.

 

Like:

POPULAR

US Government Wants To Microchip All Kids
McDonald’s French Fries Found to Contain Silly Putty Ingredient and Petroleum Chemical
Last year’s flu vaccine was a total bust, yet the CDC claims it was a “grand success”
The Longevity Breakthrough Scientists and Doctors are raving about
Five ways your digestion has been silently destroyed
How To Flush Nicotine Out of Your Body Naturally
Thanks, check your inbox for our email

Terms & Conditions

1. AGREEMENT
By using this website, you are agree, without limitation or qualification, to be bound by, and to comply with, these Terms and Conditions and any other posted guidelines or rules applicable to any individual ITMC web site.

2. RIGHT TO ACCESS
You acknowledge and agree that ITMC may terminate your access to the ITMC or to any of the Products and Services should you fail to comply with the Terms and Conditions or any other guidelines and rules published by ITMC. Any such termination shall be in ITMC's sole discretion and may occur without prior notice, or any notice. ITMC further reserves the right to terminate any user's access to the ITMC or to any of the Products and Services for any conduct that ITMC, in its sole discretion, believes is or may be directly or indirectly harmful to other users, to ITMC or its subsidiaries, affiliates, or business contractors, or to other third parties, or for any conduct that violates any local, state, federal, or foreign laws or regulations. ITMC further reserves the right to terminate any user's access to the ITMC for any reason or for no reason at all, in ITMC's sole discretion, without prior notice, or any notice.

3. COPYRIGHT
All information contained on this site is copyright (c) 2019 by TheITMC. All rights reserved. The information contained on this site may not be copied, published, distributed, broadcast or otherwise used for any purpose whatsoever without the prior written consent of ITMC.

4. PROFESSIONAL ADVICE
No information on this site is intended as, or shall be construed as, legal, financial, medical or expert advice of any kind. ITMC is not responsible for typographical errors, editing errors, or news source errors. THE ITMC STRONGLY SUGGESTS THAT YOU SEEK ADVICE FROM A COMPETENT PROFESSIONAL REGARDING ISSUES IN ANY PROFESSIONAL FIELD.

5. DISCLAIMER OF WARRANTIES
THE INFORMATION ON THIS WEBSITE IS PROVIDED "AS IS," WITH NO WARRANTIES WHATSOEVER. ALL EXPRESS, IMPLIED, AND STATUTORY WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF PROPRIETARY RIGHTS, ARE EXPRESSLY DISCLAIMED TO THE FULLEST EXTENT PERMITTED BY LAW. TO THE FULLEST EXTENT PERMITTED BY LAW, ITMC DISCLAIMS ANY WARRANTIES FOR THE SECURITY, RELIABILITY, TIMELINESS, AND PERFORMANCE OF THE INFORMATION ON THIS WEBSITE. TO THE FULLEST EXTENT PERMITTED BY LAW, ITMC DISCLAIMS ANY WARRANTIES FOR OTHER SERVICES OR GOODS RECEIVED THROUGH OR ADVERTISED ON THE WEBSITE OR RECEIVED THROUGH ANY LINKS PROVIDED IN THE WEBSITE, AS WELL AS FOR ANY INFORMATION OR ADVICE RECEIVED THROUGH THE WEBSITE OR THROUGH ANY LINKS PROVIDED IN THE WEBSITE. ITMC SIMILARLY DISCLAIMS, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY WARRANTIES FOR ANY INFORMATION OR ADVICE OBTAINED THROUGH THE WEBSITE.

YOU EXPRESSLY UNDERSTAND AND AGREE THAT ITMC DISCLAIMS ANY AND ALL RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS, LEGALITY, RELIABILITY, OR OPERABILITY OR AVAILABILITY OF INFORMATION OR MATERIAL IN THE WEBSITE. ITMC DISCLAIMS ANY RESPONSIBILITY FOR THE DELETION, FAILURE TO STORE, MISDELIVERY, OR UNTIMELY DELIVERY OF ANY INFORMATION OR MATERIAL. ITMC DISCLAIMS ANY RESPONSIBILITY OR LIABILITY FOR ANY HARM RESULTING FROM DOWNLOADING OR ACCESSING ANY INFORMATION OR MATERIAL THROUGH THE WEBSITE, INCLUDING, WITHOUT LIMITATION, FOR HARM CAUSED BY VIRUSES OR SIMILAR CONTAMINATION OR DESTRUCTIVE FEATURES. ITMC MAKES NO WARRANTY REGARDING THE RELIABILITY OR ACCESSIBILITY OF WEB PAGES OR ANY STORAGE FACILITIES OFFERED BY ITMC.

YOU UNDERSTAND AND AGREE THAT ANY MATERIAL DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE WEBSITE IS DONE AT YOUR OWN DISCRETION AND RISK AND THAT YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGES TO YOUR COMPUTER SYSTEM OR LOSS OF DATA THAT RESULTS IN THE DOWNLOAD OF SUCH MATERIAL.

Some jurisdictions do not allow the disclaimer of implied warranties. In such jurisdictions, the foregoing disclaimers may not apply to you insofar as they relate to implied warranties.

6. LIMITATION OF LIABILITY
YOU EXPRESSLY UNDERSTAND AND AGREE THAT UNDER NO CIRCUMSTANCES SHALL TRUTH PUBLISHING, INC. ("ITMC") ITS EMPLOYEES, OFFICERS, WRITERS, CONTRACTORS, OR PRINCIPALS BE LIABLE TO ANY USER'S USE OR MISUSE OF AND RELIANCE ON THE WEBSITE. SUCH LIMITATION OF LIABILITY SHALL APPLY TO PREVENT RECOVERY OF DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, AND PUNITIVE DAMAGES (EVEN IF ITMC OR ITS LICENSORS HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES). SUCH LIMITATION OF LIABILITY SHALL APPLY WHETHER THE DAMAGES ARISE FROM USE OR MISUSE OF AND RELIANCE ON THE WEBSITE, FROM INABILITY TO USE THE WEBSITE, OR FROM THE INTERRUPTION, SUSPENSION, OR TERMINATION OF THE WEBSITE (INCLUDING SUCH DAMAGES INCURRED BY THIRD PARTIES).

SUCH LIMITATION SHALL ALSO APPLY WITH RESPECT TO DAMAGES INCURRED BY REASON OF OTHER SERVICES OR GOODS RECEIVED THROUGH OR ADVERTISED ON THE WEBSITE OR RECEIVED THROUGH ANY LINKS PROVIDED IN THE WEBSITE, AS WELL AS BY REASON OF ANY INFORMATION OR ADVICE RECEIVED THROUGH OR ADVERTISED ON THE WEBSITE OR RECEIVED THROUGH ANY LINKS PROVIDED IN THE WEBSITE. SUCH LIMITATION SHALL APPLY, WITHOUT LIMITATION, TO THE COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, LOST PROFITS, OR LOST DATA. SUCH LIMITATION SHALL APPLY WITH RESPECT TO THE PERFORMANCE OR NON-PERFORMANCE OF THE WEBSITE OR ANY INFORMATION OR MERCHANDISE THAT APPEARS ON, OR IS LINKED OR RELATED IN ANY WAY TO, THE ITMC. SUCH LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. SUCH LIMITATION SHALL APPLY TO THE FULLEST EXTENT PERMITTED BY LAW.

SUCH LIMITATION OF LIABILITY SHALL ALSO APPLY TO ANY DAMAGE CAUSED BY LOSS OF ACCESS TO, DELETION OF, FAILURE TO STORE, FAILURE TO BACK UP, OR ALTERATION OF WEB PAGES OR OTHER CONTENT STORED THROUGHT THE ITMC.

UNDER NO CIRCUMSTANCES SHALL ITMC OR ITS LICENSORS BE HELD LIABLE FOR ANY DELAY OR FAILURE IN PERFORMANCE RESULTING DIRECTLY OR INDIRECTLY FROM ACTS OF NATURE, FORCES, OR CAUSES BEYOND ITS REASONABLE CONTROL, INCLUDING, WITHOUT LIMITATION, INTERNET FAILURES, COMPUTER EQUIPMENT FAILURES, TELECOMMUNICATION EQUIPMENT FAILURES, OTHER EQUIPMENT FAILURES, ELECTRICAL POWER FAILURES, STRIKES, LABOR DISPUTES, RIOTS, INSURRECTIONS, CIVIL DISTURBANCES, SHORTAGES OF LABOR OR MATERIALS, FIRES, FLOODS, STORMS, EXPLOSIONS, ACTS OF GOD, WAR, GOVERNMENTAL ACTIONS, ORDERS OF DOMESTIC OR FOREIGN COURTS OR TRIBUNALS, NON-PERFORMANCE OF THIRD PARTIES, OR LOSS OF OR FLUCTUATIONS IN HEAT, LIGHT, OR AIR CONDITIONING.

In some jurisdictions, limitations of liability are not permitted. In such jurisdictions, the foregoing limitation may not apply to you.

7. EXTERNAL LINKS
ITMC may provide, or third parties may provide, links to other sites or resources located on the World Wide Web by allowing a user to leave the ITMC to access third-party material or by bringing the third party material into this site via "inverse" hyperlinks and framing technology. ITMC has no control over such sites and resources. You acknowledge and agree that ITMC is not responsible for the availability of such external sites or resources, and does not endorse and is not responsible or liable for any content, advertising, products, or other materials on or available from such sites or resources. You further acknowledge and agree that ITMC shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any such content, goods or services available on or through any such site or resource.

Your correspondence or business dealings with, or participation in promotions of, advertisers found on or through the ITMC Products and Services, including payment and delivery of related goods or services, and any other terms, conditions, warranties or representations associated with such dealings, are solely between you and such advertiser. You agree that ITMC shall not be responsible or liable for any loss or damage of any sort incurred as the result of any such dealings or as the result of the presence of such advertisers on the Product and Services.

ITMC encourages you to exercise discretion while using the Products and Services to browse the Internet. ITMC may produce automated search results or otherwise link you to sites containing information that some people may find inappropriate or offensive. ITMC makes no representations concerning any effort to review the content of any of the sites listed in automated search results, or of any of the sites otherwise linked to the ITMC web sites. ITMC shall not be held responsible for the accuracy, copyright or trademark compliance, legality, or decency of material contained in sites listed in the ITMC' search results or otherwise linked to the ITMC web sites or provided to the ITMC by third parties.

8. Linking to the ITMC
The ITMC offers a non-assignable, non-transferable, and non-exclusive license to link to the ITMC'S web sites, using the ITMC logos and search boxes, subject to the following provisions. The ITMC logos and search boxes may be placed on a Web site for the sole purpose of creating a link to the ITMC and allowing users of your site to access the ITMC. The ITMC logos and search boxes may not be used for any other purpose, including, among other purposes, to suggest sponsorship by, or affiliation with, or endorsement by the ITMC. The ITMC logos and search boxes may only be used in accordance with the instructions found here, and may only be used in the exact size, shape, colors, design, and configuration as found on those web pages. The ITMC logos and search boxes may not be altered in any manner. The ITMC logos and search boxes must appear by themselves, with reasonable spacing (at least the height of the logo) between each side of the applicable logo or search box and other graphic or textual elements. The ITMC logos and search boxes may not be used to disparage the ITMC, its products or services, or in a manner which, in ITMC's reasonable judgment, may diminish or otherwise damage ITMC's good will in the ITMC logos. By using any such ITMC logo or search box, you acknowledge that the ITMC has exclusive rights to the logo or search box, and that all good will generated through your use of the logo or search box will inure to the benefit of the ITMC. ITMC reserves the right to revoke this license or to alter its terms from time to time, for any or no reason, with or without notice. ITMC reserves the right to take action against any use that does not conform to these provisions.

9. NO LICENSE; INTELLECTUAL PROPERTY OF ITMC AND OTHERS
Except as expressly provided, nothing within any of the WEBSITE shall be construed as conferring any license under any of the ITMC's or any third party's intellectual property rights, whether by estoppel, implication, waiver, or otherwise. Without limiting the generality of the foregoing, you acknowledge and agree that certain Content available through and used to operate the ITMC and the WEBSITE is protected by copyright, trademark, patent, or other proprietary rights of ITMC and its affiliates, licensors, and service providers. Except as expressly provided to the contrary, you agree not to modify, alter, or deface any of the trademarks, service marks, or other intellectual property made available by ITMC in connection with the WEBSITE. You agree not to hold yourself out as in any way sponsored by, affiliated with, or endorsed by ITMC, any of ITMC's affiliates, or any of ITMC's service providers. You agree not to use any of the trademarks or service marks or other Content accessible through the ITMC of any purpose other than the purpose for which such Content is made available to users by ITMC. You agree not to defame or disparage ITMC, the trademarks or service marks of ITMC, or any aspect of the WEBSITE. You agree not to adapt, translate, modify, decompile, disassemble, or reverse engineer the WEBSITE or any software or programs used in connection with the WEBSITE or the ITMC.

10. INDEMNITY AND RELEASE
By using the ITMC web sites you agree to indemnify ITMC, Inc. and its parents, subsidiaries, affiliates, officers, employees, and licensors and hold them harmless from any and all claims and expenses, including attorney's fees, arising from your use of the ITMC web sites, your use of the WEBSITE, or your submission of ideas and/or related materials to ITMC or from any person's use of any account or password you maintain with any portion of the ITMC, regardless of whether such use is authorized by you. By using the ITMC, using the WEBSITE, or submitting any ideas and/or related materials to ITMC, you are hereby agreeing to release ITMC and its parents, subsidiaries, affiliates, officers, employees, and licensors from any and all claims, demands, debts, obligations, damages (actual or consequential), costs, and expenses of any kind or nature whatsoever, whether known or unknown, suspected or unsuspected, disclosed or undisclosed, that you may have against them arising out of or in any way related to such disputes and/or to the WEBSITE or to any disputes regarding use of ideas and/or related materials submitted to ITMC. YOU HEREBY AGREE TO WAIVE ALL LAWS THAT MAY LIMIT HE EFFICACY OF SUCH RELEASES. FOR EXAMPLE, YOU SPECIFICALLY AGREE TO WAIVE THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES

"A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IS KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR."

11. LIMITATION OF ACTIONS
You acknowledge and agree that, regardless of any statute or law to the contrary, any claim or cause of action you may have arising out of, or relating to, your use of the ITMC or the WEBSITE must be filed within one (1) year after such claim or cause of action arises, or forever be barred.

12. FAIR USE
The ITMC publishes excerpts and summaries from copyrighted works under Fair Use, which allows the use of copyrighted materials for purposes of commentary and criticism for the public interest. ITMC transforms summaries of the original copyrighted work into a new format and adds new information and value in the form of commentary or criticism.

ITMC has no intention to compete with the original copyrighted content. Rather, it is ITMC's intention to promote such content and deliver readers to such content. Accordingly, when ITMC cites a copyrighted work for commentary or criticism, ITMC acknowledges the original source and places a clickable link that offers users the opportunity to click directly to the original source of such information. The original publishers benefit from such links in terms of delivered audience, attention and potential advertising revenues, for which ITMC requests absolutely no payment or consideration.

13. INTELLECTUAL PROPERTY INFRINGEMENT CLAIMS
It is the policy of the ITMC to respond expeditiously to claims of intellectual property infringement. ITMC will promptly process and investigate notices of alleged infringement and will take appropriate actions under the Digital Millennium Copyright Act ("DMCA") and other applicable intellectual property laws. Upon receipt of notices complying or substantially complying with the DMCA, the ITMC will act expeditiously to remove or disable access to any material claimed to be infringing or claimed to be the subject of infringing activity and will act expeditiously to remove or disable access to any reference or link to material or activity that is claimed to be infringing. The ITMC will terminate access for subscribers and account holders who are repeat infringers. Notices of claimed infringement should be directed to: contact@theitmc.com

Please put "Notice of Infringement" in the subject line of all such notifications. When ITMC removes or disables access to any material claimed to be infringing, ITMC may attempt to contact the user who has posted such material in order to give that user an opportunity to respond to the notification, although ITMC makes no promise to do so. Any and all counter notifications submitted by the user will be furnished to the complaining party. ITMC will give the complaining party an opportunity to seek judicial relief in accordance with the DMCA before ITMC replaces or restores access to any material as a result of any counter notification.

14. ARBITRATION, GOVERNING LAW AND FORUM FOR DISPUTES
Unless expressly stated to the contrary elsewhere within the WEBSITE, all legal issues arising from or related to the use of the WEBSITE shall be construed in accordance with, and all questions with respect thereto shall be determined by, the laws of Taiwan, R.O.C. applicable to contracts entered into and wholly to be performed within said state. Any controversy or claim arising out of or relating to these Terms and Conditions or any user's use of the WEBSITE shall be settled by binding arbitration in accordance with the commercial arbitration rules of the American Arbitration Association. Any such controversy or claim shall be arbitrated on an individual basis, and shall not be consolidated in any arbitration with any claim or controversy of any other party. The arbitration shall be conducted in Taiwan, R.O.C., and judgment on the arbitration award may be entered into in any state or federal court in Taiwan, R.O.C. having jurisdiction thereof. Any party seeking temporary or preliminary injunctive relief may do so in any state or federal court in Taiwan, R.O.C. having jurisdiction thereof. Except as set forth above, the state and federal courts of Taiwan, R.O.C. shall be the exclusive forum and venue to resolve disputes arising out of or relating to these Terms and Conditions or any user's use of the WEBSITE. By using the WEBSITE and thereby agreeing to these Terms and Conditions, users consent to personal jurisdiction and venue in the state and federal courts in Taiwan, R.O.C. with respect to all such disputes.

15. CHANGES IN TERMS AND CONDITIONS AND CHANGES IN WEBSITE
The ITMC reserves the right to modify the WEBSITE from time to time, for any reason, and without notice, including the right to terminate the WEBSITE. The ITMC reserves the right to modify these Terms and Conditions from time to time, without notice. Please review these Terms and Conditions from time to time so you will be apprised of any changes.

16. MERGER
These Terms and Conditions constitute the entire agreement between the parties with respect to the subject matter contained herein and supersedes any other agreement, proposals and communications, written or oral, between ITMC's representations and you with respect to the subject matter hereof; except that any other terms and conditions located on any individual ITMC web site or in connection with the WEBSITE are incorporated herein by reference to the extent they do not conflict with these Terms and Conditions. To the extent that any other terms and conditions or terms of service conflict with these Terms and Conditions, those other provisions shall control with respect to the use of the particular web site and any information available on or through the web site or the respective content location at which those other provisions may be found.

17. NON-WAIVER AND SEPARABILITY
ITMC's failure to exercise any right or provision of these Terms and Conditions shall not constitute a waiver of such right or provision. If a court of competent jurisdiction holds any provision of these Terms and Conditions to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties' intentions as reflected in the provision, and agree that the other provisions of these Terms and Conditions remain in full force and effect.

18. NO RESALE, ASSIGNMENT, OR SUBLICENSING
You agree not to resell, assign, sublicense, otherwise transfer, or delegate your rights or obligations under these Terms and Conditions without prior express written authorization of ITMC.

19. SUCCESSORS AND ASSIGNS
Without in any way limiting the prohibition on your resale, assignment, sublicensing, or other transfer of rights or obligations, these Terms and Conditions shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, successors, and assigns.

20. TERMINATION; SURVIVAL
These Terms and Conditions shall continue in effect for as long as you use the WEBSITE, unless specifically terminated earlier by ITMC. All provisions of these Terms and Conditions which impose obligations continuing in their nature shall survive termination of these Terms and Conditions.

21. COMMUNICATIONS WITH USERS
You consent to receive communications from ITMC concerning your use of the WEBSITE ("Communications"). The Communications may be those that ITMC is required to send to you by law concerning the WEBSITE ("Required Communications"). The Communications may also be those that ITMC sends to you for other reasons. You consent to receive Communications electronically. ITMC may provide these Communications to you by sending an email to the email address you provided or by posting the Communication on the ITMC. You also consent to receive Communications by telephone or by postal mail sent to the postal address you provided in connection with your account, if any. You may change the email or postal address to which ITMC sends Communications by visiting your account information page.

22. SUBMISSIONS OF IDEAS
The ITMC is always improving its WEBSITE and developing new features. If you have ideas regarding improvements or additions to the ITMC, we would like to hear them -- but any submission will be subject to these Terms and Conditions. UNDER NO CIRCUMSTANCES SHALL ANY DISCLOSURE OF ANY IDEA OR RELATED MATERIALS TO ITMC BE SUBJECT TO ANY OBLIGATION OF CONFIDENTIALITY OR EXPECTATION OF COMPENSATION. BY SUBMITTING THE IDEA AND/OR ANY RELATED MATERIAL TO ITMC, YOU ARE WAIVING ANY AND ALL RIGHTS THAT YOU MAY HAVE IN THE IDEA OR ANY RELATED MATERIALS AND ARE REPRESENTING AND WARRANTING TO ITMC THAT THE IDEA AND/OR RELATED MATERIALS ARE WHOLLY ORIGINAL WITH YOU, THAT NO ONE ELSE HAS ANY RIGHTS IN THE IDEA AND/OR MATERIALS AND THAT ITMC IS FREE TO IMPLEMENT THE IDEA AND TO USE THE MATERIALS IF IT SO DESIRES, AS PROVIDED OR AS MODIFIED BY ITMC, WITHOUT OBTAINING PERMISSION OR LICENSE FROM ANY THIRD PARTY.

23. VIOLATIONS OF TERMS AND CONDITIONS
Should you violate these Terms and Conditions or any other rights of ITMC and the ITMC, ITMC reserves the right to pursue any and all legal and equitable remedies against you, including, without limitation, terminating any and all access and or user accounts on any and all of the ITMC web sites.

24. SUBMITTED CONTENT
You hereby agree that all content you submit to ITMC, via web forms, email to the editor, email to employees, phone calls, faces or other form of communication shall become the sole property of ITMC and may be used by ITMC in any way whatsoever, without limitation.

We hope your enjoyment of ITMC' WEBSITE will be enhanced by the application of these Terms and Conditions. It is our belief that your understanding of the guidelines we have set forth will allow the ITMC community to continue to be a place where each of us can prosper, grow, and enjoy ourselves within an open and non-threatening environment. Thank you for taking the time to read these Terms and Conditions and we hope you enjoy our WEBSITE.

Privacy Policy

This Privacy Policy statement is made by the ITMC ("ITMC", "we", "us" or "our") and is effective as of 25th May 2018. Here at ITMC.com, we are committed to you and to protecting your privacy rights. We are committed to fulfilling our responsibilities under the European Union's General Data Protection Regulation ("GDPR") in relation to the collection, retention, use, and other processing of personal data that is obtained when EU data subjects visit and interact with the Site. We may use it to periodically inform you about changes on our Web Site and new products and services. We do not sell, trade or rent your personal information to any person or entity not authorized by or associated with us.

ITMC's Privacy Commitment

ITMC ask for only the least amount of information necessary, gathering only what we believe is essential for doing business, or for the specific transaction at hand. We let customers know the information we have on them and allow them to opt out of specific engagements.

The goal of this policy is to make explicit the information we gather on our customers and users, how we will use it, and how we will not. This policy is unfortunately longer than we would like, but we must unambiguously address all the relevant cases. We will try and keep the language simple and direct as much as possible.

Scope of this Privacy Policy

This Privacy Policy applies to the products and services provided by ITMC through these websites, our mobile applications, and applications posted by ITMC on ITMC' websites. This Privacy Policy does not apply to any of our websites, products or services that have a separate privacy policy.

This Privacy Policy is divided into two parts:

Part I – Information ITMC.com collects and controls

This part deals with how ITMC collects and uses information about website visitors, potential customers, users of ITMC's products and services, and others who contact ITMC through forms or email addresses published on or linked to our websites.

Part II – General

This part deals with topics that are relevant to other general topics such as ITMC's security commitments and how we will inform you when we change this Privacy Policy.

Part I – Information ITMC collects and controls

What information ITMC collects

We collect information about you only if we need the information for some legitimate purpose. ITMC will have information about you only if (a) you have provided the information yourself or (b) ITMC has automatically collected the information. Below we describe the various scenarios that fall under each of those three categories and the information collected in each one.

Information that you provide us

  1. Account signup: When you sign up for an account to access one or more of our services, we ask for information such as your name and email address to complete the account signup process. You may also be required to choose a unique username and a password for accessing the created account.
  2. Summit registrations and other form submissions: We record information that you submit when you (i) register for any event such as webinars or seminars, (ii) subscribe to our newsletter or any other mailing list, (iii) submit a form in order to download ebooks, whitepaper, or other materials, (iv) participate in contests or respond to surveys, or (v) submit a form to request customer support or to contact ITMC for any other purpose.
  3. Payment processing: When you buy something from us, we ask you to provide your name, contact information, and credit card information or other payment account information. When you submit your card information, we store the name and address of the cardholder, the expiry date and the last four digits of the credit card number. We do not store the actual credit card number. For quick processing of future payments, if you have given us your approval, we may store your credit card information or other payment information in an encrypted format in the secured servers of our Payment Gateway Service Providers.
  4. Testimonials: When you authorize us to post testimonials about our products and services on websites, we may include your name and other personal information in the testimonial. You will be given an opportunity to review and approve the testimonial before we post it. If you wish to update or delete your testimonial, you can contact us at contact@theitmc.com
  5. Interactions with ITMC: We may record, analyze and use your interactions with us, including email, telephone, and chat conversations with our sales and customer support professionals, for improving our interactions with you and other customers.

Information that we collect automatically

  1. Log files: Like most standard website servers, we use log files. This includes internet protocol (IP) addresses, browser type, internet service provider (ISP), referring/exit pages, platform type, date/time stamp, and number of clicks to analyze trends, administer the site, track user's movement in the aggregate, and gather broad demographic information for aggregate use. IP addresses, etc. are not linked to other personally identifiable information.
  2. Cookies and Other Similar Technologies: Technologies such as cookies or similar technologies are used by ITMC. These technologies are used in analyzing trends, administering the site, and to gather demographic information about our user base as a whole.

How We Use Cookies and Other Similar Technologies

To improve the user experience of our Site, ITMC may use the following "cookies".

Provider Purpose
Disqus To enable comment and discussion features on our website.
Vimeo To enable functionality with video features.
Facebook Connect To enable functionality with social media features.
Pinterest To enable functionality with social media features.
Twitter Button To enable functionality with social media features.
SteemIt To enable functionality with social media
Mewe To enable functionality with social media
Gab.ai To enable functionality with social media

Purposes for using information

In addition to the purposes mentioned above, we may use your information for the following purposes:

Your choice in information use

Opt out of non-essential electronic communications: You may opt out of receiving newsletters and other non-essential messages by using the 'unsubscribe' function included in all such messages. However, you will continue to receive notices and essential transactional emails.

Disable cookies: You can disable browser cookies before visiting our websites. However, if you do so, you may not be able to use certain features of the websites properly.

Optional information: You can always choose not to fill in non-mandatory fields when you submit any form linked to our websites.

Who we share your information with

We do not sell any personal information. We share your information only in the ways that are described in this Privacy Policy, and only with parties who adopt appropriate confidentiality and security measures.

Employees and independent contractors: Employees and independent contractors of all ITMC group entities have access to the information covered in Part I on a need-to-know basis. We require all employees and independent contractors of ITMC group entities to follow this Privacy Policy for personal information that we share with them.

Third-party service providers: We may need to share your personal information and aggregated or de-identified information with third-party service providers that we engage, such as marketing and advertising partners, event organizers, web analytics providers and payment processors. These service providers are authorized to use your personal information only as necessary to provide these services to us.

Your rights with respect to information we hold about you as a controller

If you are in the European Economic Area (EEA), you have the following rights with respect to information that ITMC holds about you. ITMC undertakes to provide you the same rights no matter where you choose to live.

Right to access: You have the right to access (and obtain a copy of, if required) the categories of personal information that we hold about you, including the information's source, purpose and period of processing, and the persons to whom the information is shared

Right to rectification: You have the right to update the information we hold about you or to rectify any inaccuracies. Based on the purpose for which we use your information, you can instruct us to add supplemental information about you in our database.

Right to erasure: You have the right to request that we delete your personal information in certain circumstances, such as when it is no longer necessary for the purpose for which it was originally collected.

Right to restriction of processing: You may also have the right to request to restrict the use of your information in certain circumstances, such as when you have objected to our use of your data but we need to verify whether we have overriding legitimate grounds to use it.

Right to data portability: You have the right to transfer your information to a third party in a structured, commonly used and machine-readable format, in circumstances where the information is processed with your consent or by automated means.

Right to object: You have the right to object to the use of your information in certain circumstances, such as the use of your personal information for direct marketing.

Right to complain: You have the right to complain to the appropriate supervisory authority if you have any grievance against the way we collect, use or share your information. This right may not be available to you if there is no supervisory authority dealing with data protection in your country.

Retention of information

We retain your personal information for as long as it is required for the purposes stated in this Privacy Policy. Sometimes, we may retain your information for longer periods as permitted or required by law, such as to maintain suppression lists, prevent abuse, if required in connection with a legal claim or proceeding, to enforce our agreements, for tax, accounting, or to comply with other legal obligations. When we no longer have a legitimate need to process your information, we will delete or anonymize your information from our active databases. We will also securely store the information and isolate it from further processing on backup discs until deletion is possible.

Part II – General

Children's personal information

Our products and services are not directed to individuals under 13. ITMC does not knowingly collect personal information from children who are under 13 years of age. If we become aware that a child under 13 has provided us with personal information, we will take steps to delete such information. If you believe that a child under 13 years has provided personal information to us, please write to contact@theitmc.com with the details, and we will take the necessary steps to delete the information we hold about that child.

How secure is your information

At ITMC, we take data security very seriously. We have taken steps to implement appropriate administrative, technical & physical safeguards to prevent unauthorized access, use, modification, disclosure or destruction of the information you entrust to us. If you have any concerns regarding the security of your data, we encourage you to write to us at reply@ITMC.com with any questions.

Locations and international transfers

By accessing or using our products and services or otherwise providing personal information or service data to us, you consent to the processing, transfer, and storage of your personal information or Service Data within the United States of America, the European Economic Area (EEA) and other countries where ITMC operates. Such transfer is subject to a group company agreement that is based on EU Commission's Model Contractual Clauses.

External links on our websites

Some pages of our websites may contain links to websites that are not linked to this Privacy Policy. If you submit your personal information to any of these third-party sites, your personal information is governed by their privacy policies. As a safety measure, we recommend that you not share any personal information with these third parties unless you've checked their privacy policies and assured yourself of their privacy practices.

Blogs and forums

We offer publicly accessible blogs and forums on our websites. Please be aware that any information you provide on these blogs and forums may be used to contact you with unsolicited messages. We urge you to be cautious in disclosing personal information in our blogs and forums. ITMC is not responsible for the personal information you elect to disclose publicly. Your posts and certain profile information may remain even after you terminate your account with ITMC. To request the removal of your information from our blogs and forums, you can contact us at contact@theitmc.com

Social media widgets

Our websites include social media widgets such as Twitter "tweet" buttons that let you share articles and other information. These widgets may collect information such as your IP address and the pages you navigate in the website, and may set a cookie to enable the widgets to function properly. Your interactions with these widgets are governed by the privacy policies of the companies providing them.

Disclosures in compliance with legal obligations

We may be required by law to preserve or disclose your personal information and service data to comply with any applicable law, regulation, legal process or governmental request, including to meet national security requirements.

Enforcement of our rights

We may disclose personal information and service data to a third party if we believe that such disclosure is necessary for preventing fraud, investigating any suspected illegal activity, enforcing our agreements or policies, or protecting the safety of our users.

Compliance with this Privacy Policy

We make every effort, including periodic reviews, to ensure that personal information you provide is used in conformity with this Privacy Policy. If you have any concerns about our adherence to this Privacy Policy or the manner in which your personal information is used, kindly write to us contact@theitmc.com We'll contact you, and if required, coordinate with the appropriate regulatory authorities to effectively address your concerns.

Your consent

By using our Web Site, you consent to the collection and use of information by us as set forth in this privacy statement. We reserve the right to modify, alter or otherwise update our privacy policy, and we will post those changes on this page so that you will always be aware of what information we collect, how we use it, and under what limited circumstances we disclose it. Continued access or use of the Web Site shall constitute your express acceptance of any modifications, alterations or updates to this privacy statement. However, please note that unless we obtain your express consent, any revised Privacy Policy will apply only to information collected after such time as the revised Privacy Policy takes effect. If at any point we decide to use Personally Identifiable Information in a manner different from that stated at the time it was collected, we will notify you by way of email and you will then have a choice whether or not we can use such information in this different manner. If you are concerned about how your personal information is used, you should check back at Privacy Policy periodically.

Contact Information

If you have any questions regarding our privacy policy, please contact us at contact@theitmc.com.

You may also contact us at: